Clinical trials: Simvastatin Multiple Sclerosis
Secondary Progressive Multiple Sclerosis
Simvastatin in Secondary Progressive Multiple Sclerosis
Multiple sclerosis (MS) is a neurological condition which is a common cause of disability in young people. It is thought to be an autoimmune condition, where the body's immune system begins to attack itself.
- Trial name
- MS-OPT (NCT03896217)
- Testing
- Simvastatin
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- University College, London
Lymphangioleiomyomatosis, Tuberous Sclerosis Complex
Safety of Simvastatin in LAM and TSC
The purpose of this research study is to see if simvastatin can be taken safely in patients with either LAM or TSC, who are already being treated with everolimus or sirolimus.
- Trial name
- SOS (NCT02061397)
- Testing
- Simvastatin, Sirolimus Oral Product, Everolimus Oral Product
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Pennsylvania
Secondary Progressive Multiple Sclerosis
Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis
To determine whether simvastatin at a dose of 80mg can reduce the rate of whole brain atrophy, as measured by MRI, over a 2-year time-period when compared to placebo.
- Trial name
- MS-STAT (NCT00647348)
- Testing
- Simvastatin
- Where
- 3 sites in United Kingdom
- Volunteers
- 140 people
- Sponsor
- Imperial College London